The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The selectivity of β‐adrenoceptor antagonists at the human β 1, β 2 and β 3 adrenoceptors
Open accessAbstract
β‐Adrenoceptor antagonists (‘β‐blockers’) are one of the most widely used classes of drugs in cardiovascular medicine (hypertension, ischaemic heart disease and increasingly in heart failure) as well as in the management of anxiety, migraine and glaucoma. Where known, the mode of action in cardiovascular disease is from antagonism of endogenous catecholamine responses in the heart (mainly at β 1‐adrenoceptors), while the worrisome side effects of bronchospasm result from airway β 2‐adrenoceptor blockade. The aim of this study was to determine the selectivity of β‐antagonists for the human β‐adrenoceptor subtypes. 3 H‐CGP 12177 whole cell‐binding studies were undertaken in CHO cell lines stably expressing either the human β 1‐, β 2‐ or the β 3‐adrenoceptor in order to determine the affinity of ligands for each receptor subtype in the same cell background. In this study, the selectivity of well‐known subtype‐selective ligands was clearly demonstrated: thus, the selective β 1 antagonist CGP 20712A was 501‐fold selective over β 2 and 4169‐fold selective over β 3; the β 2‐selective antagonist ICI 118551 was 550‐ and 661‐fold selective over β 1 and β 3, respectively, and the selective β 3 compound CL 316243 was 10‐fold selective over β 2 and more than 129‐fold selective over β 1. Those β 2‐adrenoceptor agonists used clinically for the treatment of asthma and COPD were β 2 selective: 29‐, 61‐ and 2818‐fold for salbutamol, terbutaline and salmeterol over β 1, respectively. There was little difference in the affinity of these ligands between β 1 and β 3 adrenoceptors. The clinically used β‐antagonists studied ranged from bisoprolol (14‐fold β 1‐selective) to timolol (26‐fold β 2‐selective). However, the majority showed little selectivity for the β 1‐ over the β 2‐adrenoceptor, with many actually being more β 2‐selective. This study shows that the β 1/β 2 selectivity of most clinically used β‐blockers is poor in intact cells, and that some compounds that are traditionally classed as ‘β 1‐selective’ actually have higher affinity for the β 2‐adrenoceptor. There is therefore considerable potential for developing more selective β‐antagonists for clinical use and thereby reducing the side‐effect profile of β‐blockers. British Journal of Pharmacology (2005) 144, 317–322. doi:10.1038/sj.bjp.0706048
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., Di Lenarda, A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., Remme, W. J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13800-7 · Cited by 1,872
A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
(2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442202 · Cited by 1,007
Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?
Konstantinou, D. M., Karvounis, H., & Giannakoulas, G. (2016) · Cardiology · doi:10.1159/000444078 · Cited by 870
Klotz, K.-N., Hessling, J., Hegler, J., Owman, C., Kull, B., Fredholm, B. B., & Lohse, M. J. (1997) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/pl00005131 · Cited by 723
Azzi, M., Charest, P. G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M., & Piñeyro, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1936664100 · Cited by 523
The two-state model of receptor activation
Leff, P. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88989-0 · Cited by 488
Bond, R. A., Leff, P., Johnson, T. D., Milano, C. A., Rockman, H. A., McMinn, T. R., Apparsundaram, S., Hyek, M. F., Kenakin, T. P., Allen, L. F., et al. (1995) · Nature · doi:10.1038/374272a0 · Cited by 416
Inverse agonist activity of beta-adrenergic antagonists.
Chidiac, P., Hebert, T. E., Valiquette, M., Dennis, M., & Bouvier, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10022-9 · Cited by 372
Adrenergic Receptors as Models for G Protein-Coupled Receptors
Kobilka, B. (1992) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.15.030192.000511 · Cited by 365
Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable Angina
Heidenreich, P. A. (1999) · JAMA · doi:10.1001/jama.281.20.1927 · Cited by 355
Drug Efficacy at G Protein–Coupled Receptors
Kenakin, T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091401.113012 · Cited by 316
Hoffmann, C., Leitz, M. R., Oberdorf-Maass, S., Lohse, M. J., & Klotz, K.-N. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0860-y · Cited by 304
COMPARISON OF SOME PROPERTIES OF PRONETHALOL AND PROPRANOLOL
Black, J. W., Duncan, W. A. M., & Shanks, R. G. (1965) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1965.tb01782.x · Cited by 275
Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism
Kenakin, T. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.2 · Cited by 213
A three-state receptor model of agonist action
Leff, P., Scaramellini, C., Law, C., & McKechnie, K. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01105-x · Cited by 196
Baker, J. G., Hall, I. P., & Hill, S. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1357 · Cited by 189
Self-citationBeta-Blocker Selectivity at Cloned Human Beta1- and Beta2-Adrenergic Receptors
Smith, C., & Teitler, M. (1999) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007784109255 · Cited by 144
Kenakin, T., & Beek, D. (1980) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32076-8 · Cited by 126
The putative β4-adrenergic receptor is a novel state of the β1-adrenergic receptor
Granneman, J. G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.2.e199 · Cited by 123
Baker, J. G., Hall, I. P., & Hill, S. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1312 · Cited by 91
Self-citationBeta-Adrenergic Blocking Drugs in the Treatment of Hypertension
Prichard, B. N. C., Cruickshank, J. M., & Graham, B. R. (2001) · Blood Pressure · doi:10.1080/080370501753400665 · Cited by 81
Pharmacological similarities and differences between β2-agonists
Lötvall, J. O. (2001) · Respiratory Medicine · doi:10.1053/rmed.2001.1139 · Cited by 73
The prevention of migraine: a critical review with special emphasis on β‐adrenoceptor blockers
Limmroth, V., & Michel, M. C. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01459.x · Cited by 69
Use of β-Adrenoceptor Blocking Drugs in Hyperthyroidism
Feely, J., & Peden, N. R. (1984) · Drugs · doi:10.2165/00003495-198427050-00003 · Cited by 60
Agonist induction and conformational selection during activation of a G-protein-coupled receptor
Hunyady, L., Vauquelin, G., & Vanderheyden, P. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00050-0 · Cited by 60
Adverse Reactions with ??-Adrenoceptor Blocking Drugs An Update
Lewis, R. V., & Lofthouse, C. (1993) · Drug Safety · doi:10.2165/00002018-199309040-00005 · Cited by 52
Efficacy in drug receptor theory: outdated concept or under-valued tool?
Kenakin, T. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01361-9 · Cited by 51
Baker, J. G., Hall, I. P., & Hill, S. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.679 · Cited by 49
Self-citationJoseph, S. S., Lynham, J. A., Molenaar, P., Grace, A. A., Colledge, W. H., & Kaumann, A. J. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0835-z · Cited by 47
Baker, J. G., Hall, I. P., & Hill, S. J. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.4.986 · Cited by 44
Self-citationSite of Action of β-Ligands at the Human β1-Adrenoceptor
Baker, J. G. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082875 · Cited by 41
Self-citationEvidence for a Secondary State of the Human β3-Adrenoceptor
Baker, J. G. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015461 · Cited by 32
Self-citationProfile of ligand binding to the porcine beta2-adrenergic receptor.
Liang, W., & Mills, S. E. (2001) · Journal of Animal Science · doi:10.2527/2001.794877x · Cited by 18
Cited by
The structure and function of G-protein-coupled receptors
Rosenbaum, D. M., Rasmussen, S. G. F., & Kobilka, B. K. (2009) · Nature · doi:10.1038/nature08144 · Cited by 2,534
Structure of a β1-adrenergic G-protein-coupled receptor
Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, P. C., Henderson, R., Leslie, A. G. W., Tate, C. G., & Schertler, G. F. X. (2008) · Nature · doi:10.1038/nature07101 · Cited by 1,344
Self-citationBiased Signaling Pathways in β 2 -Adrenergic Receptor Characterized by 19 F-NMR
Liu, J. J., Horst, R., Katritch, V., Stevens, R. C., & Wüthrich, K. (2012) · Science · doi:10.1126/science.1215802 · Cited by 697
Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling
Manglik, A., Kim, T. H., Masureel, M., Altenbach, C., Yang, Z., Hilger, D., Lerch, M. T., Kobilka, T. S., Thian, F. S., Hubbell, W. L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.043 · Cited by 665
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Metadata
- Authors
- Baker, J. G.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 144
- Issue
- 3
- Pages
- 317-322
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2168007598
- Cited by
- 537
- References
- 34
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.